by T Berger 2024Introduction - The recent GALLIUM study showed an advantage of 7% in progression free survival in favor of obinutuzumab (G) vs. rituximab
by AS Freedman Cited by 1Outline Bendamustine plus rituximab R-CHOP Obinutuzumab-based regimens Lenalidomide plus rituximab or obinutuzumab.
Rituximab, the first anti-CD20 monoclonal antibody, has dramatically improved outcomes for patients with B-cell lymphoproliferative disorders. Obinutuzumab was developed to potentiate activity and overcome resistance to rituximab. Clinical data suggest that obinutuzumab is superior to rituximab in f
Gazyva (Obinutuzumab) Gefitinib Gemcitabine Hydrochloride GEMCITABINE Rituxan (Rituximab) Rituxan Hycela (Rituximab and Hyaluronidase Human)
Obinutuzumab is different/superior to rituximab (chimeric) ofatumumab KidneyWk.
The GALLIUM study showed a progression-free survival advantage of 7% in favor of obinutuzumab vs. rituximab-based immunochemotherapies as first-line therapy in follicular lymphoma (FL) patients. Yet, the toxicity appears to be increased with obinutuzumab-based therapy. This is a multicenter retrospective-cohort study including adult FL patients comparing the toxicity of first-line rituximab vs
Obinutuzumab vs. rituximab in follicular lymphoma explained in Quick Take video:
by C Klein 2024 Cited by 38more frequent with obinutuzumab–chlorambucil than with rituximab–chlorambucil (20% vs. study of obinutuzumab–chemotherapy versus rituximab–che
Rituximab, the first anti-CD20 monoclonal antibody, has dramatically improved outcomes for patients with B-cell lymphoproliferative disorders. Obinutuzumab was developed to potentiate activity and overcome resistance to rituximab. Clinical data suggest that obinutuzumab is superior to rituximab in f
then vs than
accept vs expect
alright vs all right
its vs it's
there vs their
waist vs waste
your vs you're, you are